Mia Wilkinson

17 posts

Mia Wilkinson

@MiaSWilkinson

Translational Medicine PhD Candidate

Kingston, Ontario Katılım Kasım 2022

47 Takip Edilen24 Takipçiler

Mia Wilkinson retweetledi

Stephen L. Archer@DrStephenArcher·24 Haz

Congratulations to Dalia Miller M.Sc TMED Candidate & mentor Dr Kim Dunham-Snary on paper in Frontiers | Preclinical models of mitochondrial dysfunction: mtDNA and nuclear-encoded regulators in diverse pathologies ⁦@queensutime⁩ frontiersin.org/journals/aging…

English

412

Mia Wilkinson@MiaSWilkinson·25 Kas

I am so grateful to have had the privilege of attending #SfRBM2024, and for the opportunity to share our research and connect with experts in the field. Huge thanks to @KimSnary for your support and guidance!

Dr. Kimberly Snary@KimSnary

#SfRBM2024 has wrapped! Team @MitoMetabLab collected their abstract/travel awards (#proudPI), and we wish to congratulate @DrEMBahnson on his Mentoring Excellence Award and Dr. Holly van Remmen, the inaugural Trailblazer Award recipient. See everyone in DC next year!

English

145

Mia Wilkinson retweetledi

Stephen L. Archer@DrStephenArcher·11 May

Team TIME @Science Rendezvous ⁦@queensutime⁩ ⁦@QueensuDOM⁩ ⁦@KingstonHSC⁩ ⁦@queensualumni⁩ .The Translational Institute of Medicine scientists busy exciting young minds about science 🧬 and medicine 💊

English

525

Mia Wilkinson@MiaSWilkinson·12 May

Such a fun day! @sci_rendezvous @queensutime

Stephen L. Archer@DrStephenArcher

English

122

Mia Wilkinson retweetledi

Stephen L. Archer@DrStephenArcher·10 Kas

Research in progress with ⁦@tmedQueens⁩ students-Mia Wilkinson (Dunham-Snary lab) presented her poster on measurement of platelet metabolism as a liquid biopsy to assess muscle metabolism in cardiometabolic syndrome (for SFRBM meeting) KUDOS Mia ⁦@QueensuCPU⁩

English

1.2K

Mia Wilkinson@MiaSWilkinson·13 May

🎉🎉

Dr. Kimberly Snary@KimSnary

It was a big day for @MitoMetabLab. The first-ever paper written by one of my stellar trainees was submitted today! 🥳 Congratulations @MiaSWilkinson - en route to Montreal for COSC right after submission! 🤓 @tmedQueens preparing students well! #teamworkmakesthedreamwork

ART

197

Mia Wilkinson retweetledi

Dr. Kimberly Snary@KimSnary·12 May

Team @MitoMetabLab presenting their 'side hustles' at COSC! They never cease to raise the bar and I am such a #proudPI 🤓

English

413

Mia Wilkinson@MiaSWilkinson·21 Şub

@tmedQueens @QueensuDOM @QueensUHealth @BethanyMonteith @LintonSophia @Asish_Dasgupta @SamanthaDelios Thanks for the great summary Sam! Would you anticipate barriers to research into cheaper drugs or drug regimens from pharmaceutical companies due to the large role they play in sponsoring clinical trials?

English

Translational Medicine Graduate Program@tmedQueens·15 Şub

Check out this week's TMED Blog post written by Samantha Delios about last week's MGR presentation featuring Dr. Bethany Monteith. deptmed.queensu.ca/news/multiple-… @QueensuDOM @QueensUHealth @BethanyMonteith @LintonSophia @Asish_Dasgupta @SamanthaDelios

Queen's U Department of Medicine@QueensuDOM

Join us on Thurs. Feb 9 @ 07:45am for #MedicalGrandRounds. Dr. Bethany Monteith Ames will present "Multiple Myeloma: The Rising Cost of Cancer Care". Not on our distribution list? E-mail jillian.garrah@queensu.ca for the link!

English

735

Mia Wilkinson@MiaSWilkinson·24 Oca

@schinhail @tmedQueens @LintonSophia @Asish_Dasgupta @queensutime @QueensuDOM @QueensUHealth coupled with surveillance and monitoring during and after treatment. Figure 1 of this review summarizes this timeline very well: ahajournals.org/doi/full/10.11… 2/2

English

Translational Medicine Graduate Program@tmedQueens·18 Oca

Check out this TMED blog written by Mia Wilkinson about last week's MGR. deptmed.queensu.ca/news/contextua… @MiaSWilkinson @LintonSophia @Asish_Dasgupta @queensutime @QueensuDOM @QueensUHealth

Queen's U Department of Medicine@QueensuDOM

Join us on Thurs. Jan 12 @ 07:45am for Medical Grand Rounds. Dr. Husam Abdel-Qadir will talk about "Contextualizing the Cardiovascular Risk of Breast Cancer Treatment" Not on our distribution list? E-mail jillian.garrah @queensu.ca for the link!

English

Mia Wilkinson@MiaSWilkinson·24 Oca

@schinhail @tmedQueens @LintonSophia @Asish_Dasgupta @queensutime @QueensuDOM @QueensUHealth Thanks for the question! I think as Dr. Abdel-Qadir alluded to, as much assessment as possible would be ideal, but barriers such as imaging wait times make this a feasibility issue. Typically, at-risk patients would have preventive measures taken before and during treatment, 1/

English

Mia Wilkinson@MiaSWilkinson·24 Oca

@MattiMcfarlane @tmedQueens @LintonSophia @Asish_Dasgupta @queensutime @QueensuDOM @QueensUHealth Advancements in cardio-protective therapies, such as dexrazoxane treatment before anthracycline chemotherapy, may also be a useful strategy to protect high-risk patients. 3/

English

Matti McFarlane@MattiMcfarlane·23 Oca

@tmedQueens @MiaSWilkinson @LintonSophia @Asish_Dasgupta @queensutime @QueensuDOM @QueensUHealth Hi Mia! Excellent post and discussion. Are there certain breast cancer treatments that clinicians would prefer for a patient with CVD or a family history or CVD? Are there ways to improve care beyond post-treatment surveillance that are being researched?

English

104

Mia Wilkinson@MiaSWilkinson·24 Oca

@MattiMcfarlane @tmedQueens @LintonSophia @Asish_Dasgupta @queensutime @QueensuDOM @QueensUHealth and those with high CVD risk are managed prior to, throughout, and after treatment (i.e. a hypertensive individual would have their hypertension managed and monitored during and after treatment). 2/

English

Mia Wilkinson@MiaSWilkinson·24 Oca

@MattiMcfarlane @tmedQueens @LintonSophia @Asish_Dasgupta @queensutime @QueensuDOM @QueensUHealth Thanks for your response! To answer your first question: While some breast cancer therapies have more favourable CVD risk profiles, known cardio-toxic agents are often necessary for curative cancer treatment. Choice of therapy is dictated by tumour and patient characteristics 1/

English

Mia Wilkinson@MiaSWilkinson·24 Oca

@abby_mocho @tmedQueens @LintonSophia @Asish_Dasgupta @queensutime @QueensuDOM @QueensUHealth and relay it in a way that facilitates informed decision-making. 3/3

English

Abby Mocherniak@abby_mocho·19 Oca

@tmedQueens @MiaSWilkinson @LintonSophia @Asish_Dasgupta @queensutime @QueensuDOM @QueensUHealth @MiaSWilkinson You did a great job summarizing Dr. Abdel-Qadir's MGR presentation. Do you think that educating breast cancer patients on the risk of cardiotoxicity should be emphasized as a responsibility of physicians in order to promote informed decision-making and autonomy?

English

Mia Wilkinson@MiaSWilkinson·24 Oca

@abby_mocho @tmedQueens @LintonSophia @Asish_Dasgupta @queensutime @QueensuDOM @QueensUHealth effectively communicate these risks to patients. As I touched on in my blog post, information about treatment risks may be confusing or scary from a patient's perspective, but it is the responsibility of the physician to appropriately outline all pertinent information 2/

English

Mia Wilkinson@MiaSWilkinson·24 Oca

@abby_mocho @tmedQueens @LintonSophia @Asish_Dasgupta @queensutime @QueensuDOM @QueensUHealth Great question! Patient autonomy is very important, especially in a field such as oncology where many treatment options have significant adverse effects. Oncologists should be aware of the cardio-toxic effects of possible treatments they may prescribe, and be able to 1/

English

Mia Wilkinson retweetledi

Stephen L. Archer@DrStephenArcher·16 Oca

Proud of my colleague, Dr Kim Dunham-Snary ⁦@QueensuDOM⁩ , who just received her official Tier 2 Canada Research Chair certificate for mitochondrial metabolic research from ⁦@JustinTrudeau⁩ -lucky to have you here ⁦@queensuResearch⁩ in DBMS & the DOM!

English

3.6K

Keşfet

@queensutime @KimSnary @Science @QueensuDOM @KingstonHSC @queensualumni @sci_rendezvous @tmedQueens